A plasma viscosity test measures how strongly the liquid portion of blood resists flow. The result is influenced mainly by proteins dissolved in plasma, especially fibrinogen and immunoglobulins. Because many of these proteins increase during infection, inflammation, tissue injury, and some cancers, plasma viscosity can serve as a general inflammatory marker. It is used more commonly in the United Kingdom than in many other countries, often alongside C-reactive protein or instead of the erythrocyte sedimentation rate. A high result does not reveal where inflammation is located or identify its cause. It may also reflect abnormal immunoglobulin production, as in certain plasma cell disorders. Although the test is sometimes described as measuring “blood thickness,” it examines plasma rather than all components of whole blood. Mild inflammatory elevations are also very different from symptomatic hyperviscosity syndrome, a rare medical emergency. Interpretation requires the laboratory’s own reference interval, the degree and persistence of elevation, symptoms, and related blood and protein tests.
- Plasma viscosity reflects resistance to flow in the liquid portion of blood, not simply the number of blood cells.
- Fibrinogen and immunoglobulins are major proteins that can raise the result.
- A high value is nonspecific and may occur with infection, autoimmune inflammation, cancer, or paraproteins.
- Reference ranges depend on the analyzer, temperature, and laboratory method.
- Routine inflammatory elevations are not the same as hyperviscosity syndrome.
Table of Contents
- How the Plasma Viscosity Test Works
- Reference Ranges, Units, and Result Categories
- Why Plasma Viscosity May Be High
- Plasma Viscosity Compared With CRP and ESR
- High Plasma Viscosity Versus Hyperviscosity Syndrome
- How an Abnormal Result Is Investigated and Followed
- Preparing for the Test and Interpreting Your Result
How the Plasma Viscosity Test Works
Blood consists of cells suspended in plasma. Plasma is mostly water, but it also contains proteins, electrolytes, nutrients, hormones, and waste products. A laboratory separates or analyzes the plasma and measures its resistance to flow through a calibrated viscometer. Results are commonly expressed in millipascal-seconds, written as mPa·s or mPa/s.
Viscosity is affected by temperature, so the instrument and reporting system must use a defined measurement temperature. Many services report values standardized at 25°C, but methods differ. This is why a number from one laboratory should not be interpreted using another laboratory’s interval without checking the report.
The major biological influences are plasma proteins. Fibrinogen is an acute-phase protein that often rises during infection, tissue damage, and inflammatory disease. Immunoglobulins are antibodies; they may increase broadly during chronic immune stimulation or rise dramatically when an abnormal clone of plasma cells produces a monoclonal protein. Albumin contributes less to viscosity than large or elongated proteins and may fall during inflammation.
The test therefore provides an indirect, integrated view of protein changes rather than measuring one specific molecule. It cannot state which protein is responsible. If plasma viscosity is high, other tests may be needed to distinguish an acute-phase response from excess immunoglobulin or another cause.
“Blood thickness” is a convenient phrase, but it can be misleading. Whole-blood flow also depends on red blood cell concentration, red cell flexibility, white cell count, platelets, vessel diameter, and flow conditions. Plasma viscosity excludes most of those cellular effects. A person with a high hematocrit may have increased whole-blood viscosity even when plasma viscosity is normal, while someone with a paraprotein may have high plasma viscosity despite an ordinary red cell count.
The sample is usually taken from a vein, often into the same type of anticoagulated tube used for a full blood count. Fasting is generally not required unless other ordered tests require it. The blood draw itself carries the usual small risks of brief pain, bruising, lightheadedness, or, rarely, infection at the puncture site.
Reference Ranges, Units, and Result Categories
A commonly used adult reference interval in several UK laboratories is approximately 1.50 to 1.72 mPa·s at 25°C. That range is an example, not a universal standard. Some laboratories use different instruments, temperatures, calibrations, or intervals, and pediatric ranges may differ. Always use the range printed beside the actual result.
Results just above the upper limit may be described as borderline or equivocal. A laboratory may recommend repeating the test after an appropriate interval, particularly if the person is well and the rest of the assessment is reassuring. Greater elevations make a meaningful protein change more likely but still do not identify a cause.
One NHS laboratory provides interpretive bands such as the following:
| Example result at 25°C | Example laboratory comment | Important limitation |
|---|---|---|
| 1.50–1.72 mPa·s | Adult reference interval | Only applies to that method and laboratory |
| 1.72–1.80 mPa·s | Equivocal; repeat may be considered | Symptoms and other tests determine significance |
| 1.80–2.00 mPa·s | May fit a chronic inflammatory pattern | Not proof of chronic disease |
| 2.00–2.30 mPa·s | May fit a stronger acute-phase response | Acute and chronic causes can overlap |
| Above 2.30 mPa·s | Prompts consideration of paraprotein disorders | Not a diagnostic cutoff for myeloma |
These bands should not be transferred automatically to a report produced by another service. Even a very high result must be interpreted with symptoms and direct protein studies.
A low plasma viscosity result is less commonly a clinical concern. It may occur when plasma protein concentrations are low, including low fibrinogen or immunoglobulins, severe hypoproteinemia, or dilution. The result should be considered with albumin, total protein, liver function, clotting studies, and the clinical situation. A low value does not mean blood is flowing “too freely” in a way that needs treatment by itself.
Changes over time can be more informative than a single isolated number. A result that falls as symptoms improve may support resolution of an inflammatory process. A persistent or increasing value may justify reassessing disease activity, infection, or abnormal protein production. Trends are most reliable when measured by the same laboratory method.
Why Plasma Viscosity May Be High
Plasma viscosity rises when the amount, size, shape, or interaction of plasma proteins changes. The main causes fall into two broad groups: a polyclonal acute-phase or immune response and monoclonal protein production.
Infection and inflammation
During an acute-phase response, the liver increases production of proteins such as fibrinogen. Immunoglobulins may also increase, especially with longer-lasting immune stimulation. Possible settings include:
- bacterial, viral, fungal, or other infections;
- rheumatoid arthritis and other inflammatory joint diseases;
- vasculitis, including giant cell arteritis;
- inflammatory bowel disease;
- tissue injury, surgery, or significant trauma;
- some chronic liver, kidney, or connective-tissue disorders.
The test cannot distinguish among these conditions. A mild respiratory infection and an active autoimmune disorder can both raise the value. Conversely, a normal result does not completely exclude localized, early, or biologically unusual inflammation.
Cancer and abnormal immunoglobulins
Some cancers produce a general inflammatory response. Of particular importance are plasma cell and B-cell disorders that generate a monoclonal immunoglobulin, also called a paraprotein or M protein. Multiple myeloma and Waldenström macroglobulinemia are examples. The physical properties and concentration of the immunoglobulin affect viscosity; immunoglobulin M is especially large and can markedly impede plasma flow.
A high result does not mean a person has myeloma. Most inflammatory elevations are caused by more common conditions. However, unexplained, persistent, or substantial elevation—especially with anemia, kidney dysfunction, high total protein, bone pain, recurrent infections, weight loss, enlarged lymph nodes, or neurological and visual symptoms—may lead to tests for a monoclonal protein.
Other protein changes
Polyclonal hypergammaglobulinemia can occur in chronic infection, autoimmune disease, and liver disease. This broad rise in several antibody types may increase viscosity without a monoclonal disorder. Changes in globulin levels may offer a clue, but serum protein electrophoresis and immunofixation provide more specific information.
Dehydration may concentrate plasma components, although plasma viscosity is generally considered less dependent on simple physiological variation than some other inflammatory markers. Clinical hydration status and the rest of the chemistry panel still matter when an unexpected result is reviewed.
Plasma Viscosity Compared With CRP and ESR
Plasma viscosity, C-reactive protein, and the erythrocyte sedimentation rate are all nonspecific markers, but they measure different phenomena.
| Test | What it primarily reflects | Notable characteristics |
|---|---|---|
| Plasma viscosity | Combined effect of plasma proteins on resistance to flow | Influenced by fibrinogen and immunoglobulins; less affected by anemia and red cell shape than ESR |
| CRP | Concentration of one rapidly responsive acute-phase protein | Usually rises and falls relatively quickly; widely available |
| ESR | Rate at which red cells settle in a tube | Affected by fibrinogen and immunoglobulins but also by anemia, age, pregnancy, and red cell characteristics |
Plasma viscosity has several practical advantages. Values in healthy adults tend to occupy a narrow interval, and the measurement is not directly distorted by anemia or unusual red cell shapes in the way ESR can be. The sample may also remain analytically stable longer than an ESR sample, depending on laboratory procedures.
CRP often responds more rapidly to sudden inflammation and is widely used for acute infection and monitoring. Plasma viscosity may remain elevated longer because it reflects several proteins with different half-lives. That persistence can be helpful when following some chronic inflammatory diseases, but it may lag behind clinical improvement.
No marker is universally superior. The best choice depends on local laboratory practice, the disease being assessed, and the clinical question. Some UK services use plasma viscosity routinely, while many health systems rarely offer it and rely on CRP and ESR. Ordering all three without a specific purpose may add confusing nonspecific abnormalities rather than clarity.
An inflammatory marker panel can reveal whether several signals move together, but concordance still does not establish a diagnosis. Discordant results can occur because each marker responds at a different speed and is affected by different biological factors.
High Plasma Viscosity Versus Hyperviscosity Syndrome
A laboratory result above the reference interval is not automatically hyperviscosity syndrome. Hyperviscosity syndrome is a clinical emergency in which markedly impaired blood flow causes symptoms and organ dysfunction. It is most often associated with very high concentrations of monoclonal immunoglobulins, particularly in Waldenström macroglobulinemia, but it can occur in other hematologic disorders.
Classic manifestations involve three systems:
- Neurological: headache, dizziness, confusion, unsteady walking, hearing changes, seizures, or reduced consciousness;
- Visual: blurred or double vision, retinal bleeding, or sudden visual change;
- Bleeding: recurrent nosebleeds, gum bleeding, or other mucosal bleeding.
Shortness of breath, heart failure symptoms, weakness, and other problems may also occur. Symptom severity does not correspond perfectly to one viscosity threshold. The type of protein, rate of change, individual circulation, and measurement method all matter. Clinicians treat the patient, not merely the number.
This distinction is important because routine inflammation can produce a modest high plasma viscosity without creating dangerous flow impairment. Describing every elevation as “thick blood” may cause unnecessary alarm and can lead people to assume they need aspirin, anticoagulants, extra water, or blood-thinning supplements. Those measures do not treat protein-driven hyperviscosity and may create bleeding risk.
Suspected symptomatic hyperviscosity requires urgent hospital assessment. Treatment may include plasma exchange to remove circulating paraprotein rapidly, followed by therapy for the underlying blood disorder. It should never be managed through self-treatment or delayed while waiting for a routine appointment.
Whole-blood hyperviscosity from extreme red blood cell or white blood cell elevations is related but not identical. Polycythemia and leukostasis involve cellular components and require different evaluation. A plasma viscosity test alone cannot assess every mechanism that makes whole blood harder to circulate.
How an Abnormal Result Is Investigated and Followed
Evaluation begins with the reason the test was ordered. A mildly high value during a known infection may need no separate investigation if the clinical course is appropriate. An unexplained or persistent elevation calls for a broader review.
Common accompanying tests include:
- complete blood count for anemia, white cell changes, and platelets;
- CRP or ESR to compare inflammatory patterns;
- kidney and liver function tests;
- albumin, total protein, and calculated globulin;
- serum protein electrophoresis and immunofixation when a paraprotein is possible;
- serum free light chains and quantitative immunoglobulins in selected cases;
- urinalysis, cultures, imaging, or autoimmune tests guided by symptoms.
The history may focus on fever, pain, joint stiffness, headache, visual symptoms, infection exposure, weight loss, night sweats, recurrent infections, bone pain, numbness, and bleeding. Examination may look for swollen joints, rashes, enlarged lymph nodes, spleen enlargement, temporal artery tenderness, infection sources, or signs of organ dysfunction.
Repeating the test can clarify whether a borderline value was temporary. The timing should match the clinical question. Repeating within hours in a stable outpatient may add little, while a later comparison after an infection or treatment interval may be useful. For known inflammatory disease, clinicians may follow the trend at planned visits rather than react to every small fluctuation.
Treatment targets the cause. Antibiotics are appropriate only for a confirmed or strongly suspected bacterial infection; immunosuppressive therapy is tailored to inflammatory disease; and hematology treatment is directed at abnormal immunoglobulin production. There is no medicine prescribed solely to normalize a mildly elevated plasma viscosity number.
Preparing for the Test and Interpreting Your Result
Most people need no special preparation. Continue usual food and fluids unless another test requires fasting, and do not stop prescribed medicines unless the ordering clinician instructs you to do so. Tell the clinician about recent infection, surgery, inflammatory flares, pregnancy, cancer treatment, and any previous monoclonal protein finding.
When the result arrives, use a structured approach:
- Check the laboratory interval and units. Do not compare mPa·s values from different temperatures or methods without guidance.
- Note the degree of elevation. A borderline increase has a different implication from a substantial, persistent rise.
- Look at related results. CRP, full blood count, albumin, total protein, kidney function, and electrophoresis may point toward the mechanism.
- Match the number to symptoms. Fever and joint pain suggest a different pathway from visual change, mucosal bleeding, anemia, or bone pain.
- Compare with prior tests. A stable personal baseline may be more informative than one population cutoff.
Contact a clinician promptly for an unexplained high result accompanied by weight loss, persistent fever, drenching night sweats, bone pain, marked fatigue, recurrent infections, anemia, kidney problems, or unusually high total protein. Seek emergency care for sudden visual disturbance, confusion, severe headache, weakness, seizures, breathing difficulty, fainting, or significant mucosal bleeding.
The key message is that plasma viscosity is a broad signal of altered plasma proteins. It can help detect or monitor inflammation and can alert clinicians to excess immunoglobulins, but it cannot locate disease or name the cause. Accurate interpretation depends on the local method, the protein and blood-count context, symptoms, and the trajectory over time.
For people who monitor a chronic condition, it can help to record the test date, result, laboratory range, current symptoms, and recent treatment changes together. A numerical rise that occurs without any clinical change may be handled differently from the same rise accompanied by new pain, fever, stiffness, or fatigue. Likewise, a value can remain above range for a time after an inflammatory episode because the contributing proteins do not all return to baseline at the same speed. Decisions should therefore be based on the full pattern rather than an isolated arrow or flag on a patient portal.
References
- Plasma Viscosity 2025
- Plasma Viscosity 2023
- Directorate of Laboratory Haematology User Guide 2026
- CRP, ESR and PV Inflammation Markers – A Comparative Review 2025
- Hyperviscosity Syndrome 2025
Disclaimer
This article provides general education and cannot interpret an individual plasma viscosity result or replace medical care. Reference intervals and alarm thresholds vary by laboratory method, and a high result does not by itself diagnose inflammation, myeloma, or hyperviscosity syndrome. Sudden visual, neurological, breathing, or bleeding symptoms require urgent assessment.
